Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Starting Grant

Project description

Harnessing reactive oxygen species in cancer vaccines

Reactive oxygen species (ROS) are chemically reactive molecules derived from oxygen. They exhibit a dual role, contributing to both damage and defence. In immunity, ROS act as molecular alarms that activate immune cells to detect and eliminate cancer. Physical plasma can generate ROS and is thus emerging as a novel therapeutic tool. Plasma exposure induces oxidative stress in cancer cells, altering their surface markers and enhancing immune recognition. Beyond direct killing, ROS also oxidise biomolecules released by dying cells and amplify immune activation. The ERC-funded PriME project aims to generate a therapeutic anticancer vaccine that is based on plasma-oxidised cancer cell lysates.

Objective

Efficient anticancer immune effects are a prime medical discovery of this century. Molecular alarms drive such immune responses, signaling priming and effector cells to action. Several approaches are studied or clinically used to initiate or support such action. Yet, the perhaps evolutionary old and most conserved mechanism has been mostly off the map so far: reactive oxygen species (Physical-technical applications extend into medicine for diagnostics and also therapies, such as: cancer treatment. Tumor cells present various receptors on the cell surface, and immune cells can interact with these receptors to decide whether a cell should be eliminated or not. Therapies or other external influences can change the spectrum of the presented receptors and thus the interaction, aiming to stimulate an immune response. Once a tumor cell gets identified as harmful, an immune response is initiated to recruit cytotoxic T cells and other adaptive immune cells to reduce tumor growth. Physical plasmas are therapeutic and have antimicrobial efficacy and cancer-killing effects. Plasmas can be generated to operate at low temperatures, which enables them for medical applications, and produced reactive oxygen and nitrogen species (ROS) mainly induce biomedical effects. In tumor cells, plasma treatment leads to redox stress, followed by altered surface marker expression, which has immune-stimulating properties. However, ROS are not absent when the tumor cell dies, and further ROS-mediated mechanisms, such as oxidation of released biomolecules, continue. I hypothesize that immune-stimulatory properties of plasma are combinatory effects of molecular changes and biomolecule oxidation, suggesting that a standardized plasma treatment with maximized ROS, more precisely radical production, optimizes biomolecule oxidation and immunological consequences. My vision is to establish a novel approach to plasma-treated cancers by oxidizing cancer lysates with plasma for use as a therapeutic vaccine.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-STG

See all projects funded under this call

Host institution

LEIBNIZ-INSTITUT FUR PLASMAFORSCHUNG UND TECHNOLOGIE EV
Net EU contribution
€ 1 499 892,00
Address
FELIX HAUSDORFF STRASSE 2
17489 Greifswald
Germany
Region
Mecklenburg-Vorpommern Mecklenburg-Vorpommern Vorpommern-Greifswald
Activity type
Research Organisations
Links
Total cost
€ 1 499 892,00

Beneficiaries (1)